98 related articles for article (PubMed ID: 10086793)
1. Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma.
Thunberg U; Bånghagen M; Bengtsson M; Christensen LD; Geisler CH; Gimsing P; Lenhoff S; Mortensen BT; Olofsson T; Simonsson B; Andersen NS; Sundström C; Swedin A; Sällström JF; Thuresson B; Westin J; Carlson K
Br J Haematol; 1999 Mar; 104(3):546-52. PubMed ID: 10086793
[TBL] [Abstract][Full Text] [Related]
2. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
3. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.
Lemoli RM; Martinelli G; Olivieri A; Motta MR; Rizzi S; Terragna C; Leopardi G; Benni M; Ronconi S; Cantori I; Rondelli D; Mangianti S; Leoni P; Montanari M; Cavo M; Tura S
Br J Haematol; 1999 Nov; 107(2):419-28. PubMed ID: 10583236
[TBL] [Abstract][Full Text] [Related]
4. Unfractionated peripheral blood stem cell autografts and CD(34+)-enriched autografts have similar long-term culture initiating capacity in multiple myeloma.
Turhan AG; Bourhis JH; Bonnet ML; Novault S; Bayle C; Bennaceur A; Vainchenker W; Pico JL; Beaujean F
Hematol Cell Ther; 1999 Nov; 41(5):197-204. PubMed ID: 10651119
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
[TBL] [Abstract][Full Text] [Related]
6. CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells.
Willems P; Croockewit A; Raymakers R; Holdrinet R; van Der Bosch G; Huys E; Mensink E
Br J Haematol; 1996 Jun; 93(3):613-22. PubMed ID: 8652382
[TBL] [Abstract][Full Text] [Related]
7. A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells.
Cremer FW; Kiel K; Sucker C; Wacker J; Atzberger A; Haas R; Goldschmidt H; Moos M
Leukemia; 1997 Dec; 11 Suppl 5():S41-6. PubMed ID: 9436938
[TBL] [Abstract][Full Text] [Related]
8. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
[TBL] [Abstract][Full Text] [Related]
9. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.
Rasmussen T; Björkstrand B; Andersen H; Gaarsdal E; Johnsen HE
Exp Hematol; 2002 Jan; 30(1):82-8. PubMed ID: 11823041
[TBL] [Abstract][Full Text] [Related]
11. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.
Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
Exp Hematol; 2002 Jun; 30(6):529-36. PubMed ID: 12063019
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
[TBL] [Abstract][Full Text] [Related]
13. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
[TBL] [Abstract][Full Text] [Related]
15. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests.
Henry JM; Sykes PJ; Brisco MJ; To LB; Juttner CA; Morley AA
Br J Haematol; 1996 Mar; 92(3):614-9. PubMed ID: 8616025
[TBL] [Abstract][Full Text] [Related]
16. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield.
Kiel K; Cremer FW; Ehrbrecht E; Wallmeier M; Hegenbart U; Goldschmidt H; Moos M
Bone Marrow Transplant; 1998 Jun; 21(11):1109-15. PubMed ID: 9645573
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system.
Voena C; Locatelli G; Castellino C; Omedè P; Ladetto M; Zappone E; Milani R; Perfetti V; Boccadoro M; Pileri A; Lusso P; Villa C; Malnati M; Corradini P
Br J Haematol; 2002 Jun; 117(3):642-5. PubMed ID: 12028036
[TBL] [Abstract][Full Text] [Related]
18. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy.
Mariette X; Fermand JP; Brouet JC
Bone Marrow Transplant; 1994 Jul; 14(1):47-50. PubMed ID: 7524906
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
[TBL] [Abstract][Full Text] [Related]
20. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
